Avalo Therapeutics Inc
$ 17.95
5.77%
04 Dec - close price
- Market Cap 325,505,000 USD
- Current Price $ 17.95
- High / Low $ 18.80 / 16.63
- Stock P/E N/A
- Book Value 5.13
- EPS -13.42
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -1.75 %
- 52 Week High 19.41
- 52 Week Low 3.39
About
None
Analyst Target Price
$33.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-27 | 2024-11-07 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-09 | 2023-08-03 | 2023-05-04 | 2023-03-29 |
| Reported EPS | -2.19 | -1.92 | -1.2867 | -2.74 | -1.25 | -14.07 | -141 | -116.21 | -0.11 | -0.59 | -0.85 | -1.04 |
| Estimated EPS | -1.22 | -1.19 | -1.605 | 1.665 | -1.19 | -6.7 | -1.18 | -4.8 | -1.1 | -0.8 | -0.97 | -0.73 |
| Surprise | -0.97 | -0.73 | 0.3183 | -4.405 | -0.06 | -7.37 | -139.82 | -111.41 | 0.99 | 0.21 | 0.12 | -0.31 |
| Surprise Percentage | -79.5082% | -61.3445% | 19.8318% | -264.5646% | -5.042% | -110% | -11849.1525% | -2321.0417% | 90% | 26.25% | 12.3711% | -42.4658% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVTX
2025-11-17 16:30:00
Avalo Therapeutics (Nasdaq: AVTX) granted 114,000 nonstatutory stock options to three new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options, granted on November 4, 10, and 17, 2025, vest over four years, with 25% on the one-year anniversary and the remainder monthly over 36 months, subject to continued service. The exercise price for these options is set at the closing price on each grant date.
2025-11-17 16:30:00
Avalo Therapeutics announced the grant of inducement equity awards to three new employees, consisting of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock. These grants were approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting on the one-year anniversary of the start date and the remainder vesting monthly thereafter.
2025-10-10 00:00:00
Avalo Therapeutics, Inc. released an updated investor presentation highlighting its IL-1β therapies, specifically AVTX-009 for hidradenitis suppurativa, with Phase 2 trial data expected by mid-2026. The company projects a significant market for HS exceeding $10 billion by 2035 and anticipates its cash runway will last into 2028.
2025-10-01 07:00:00
Avalo Therapeutics has expanded its leadership team with the appointments of Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President, Human Resources. These key hires aim to strengthen the company as it advances its AVTX-009 treatment through clinical trials and scales its operations. Both individuals bring extensive experience in their respective fields within the biotech and pharmaceutical sectors.
2025-09-22 07:00:00
Avalo Therapeutics, Inc. (Nasdaq: AVTX) has appointed Kevin R. Lind to its Board of Directors, bringing over 20 years of leadership in capital markets, strategy, and business development. Lind previously guided Longboard Pharmaceuticals to a multi-billion-dollar exit and was instrumental in Arena Pharmaceuticals' turnaround. His appointment comes as Avalo advances its lead asset, AVTX-009, through a Phase 2 trial for hidradenitis suppurativa, with topline data expected mid-next year.
2025-09-16 00:00:00
Institutional investors in Avalo Therapeutics (NASDAQ:AVTX) experienced an 11% loss last week, though their longer-term gains over the past year helped mitigate overall losses. Institutions hold a significant 34% ownership, making their trading decisions impactful on the stock price. Other major shareholders include hedge funds (23%) and private equity firms (19%), while individual investors hold 19% and insiders own US$6.8 million worth of stock.
